大行評級|里昂:上調藥明康德目標價至92.4港元 列爲內地CRO板塊首選
里昂發佈研究報告指,藥明康德去年第四季經調整純利符合預期,訂單增長超預期。公司料今年持續收入按年增10%至15%,經調整淨利潤率會進一步改善。公司亦料今年資本開支會達70億至80億元,主要爲擴張中國內地、美國及新加坡的產能,另建議回購10億元A股。
該行上調藥明康德今明兩年的純利預測0%至1%,將H股目標價由73.6港元升至92.4港元,重申“跑贏大市”評級,並列爲內地CRO板塊的首選。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.